Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082511 · ClinicalTrials.gov registry record · Phase 3
GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
A Phase 3 study of Systemic Lupus Erythematosus, sponsored by Genelabs Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 114
- Enrollment target
- 20
- Study locations
NCT00082511 is a Phase 3 study of Systemic Lupus Erythematosus that has completed, run by Genelabs Technologies. The registered enrollment target is 114 participants, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00082511, a Phase 3 study of Systemic Lupus Erythematosus, has completed, sponsored by Genelabs Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 114 participants
- Enrollment target
- 20
- Study locations
Study Summary
Open label safety and efficacy follow-up.
Conditions Studied
Interventions
- DRUG Prasterone (GL701)
Study Locations (20)
California
- Wallace Rheumatic Study Center - Los Angeles
- Lifestyles Health Science Center - Rancho Mirage
- University of California San Diego - San Diego
- East Bay Rheumatology Group - San Leandro
Florida
- Center for Rheumatology, Immunology and Arthritis - Fort Lauderdale
- Rheumatology Associates of Central Florida - Orlando
- Tampa Medical Group, P.A. - Tampa
New York
- SUNY Downstate Medical Center - Brooklyn
- North Shore University Hospital, Division of Rheumatology - Manhasset
- Albert Einstein Medical School - The Bronx
Missouri
- St. John's Medical Research Group - Springfield
- Washington University School of Medicine - St Louis
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
- University of Pittsburgh - Pittsburgh
Arizona
- University of Arizona - Tucson
Illinois
- Northwestern University - Chicago
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2003-07 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082511
The ClinicalTrials.gov registry entry for NCT00082511 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (70% lower). The listed sponsor is Genelabs Technologies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Prasterone (GL701) is the first listed.
NCT00082511 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00082511 about?
NCT00082511 is a clinical study titled "GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids". Open label safety and efficacy follow-up.
What is the current status of trial NCT00082511?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 2003-07. Estimated completion is 2005-08.
What conditions does trial NCT00082511 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT00082511?
The interventions under investigation include: Prasterone (GL701) (DRUG).
Who is sponsoring clinical trial NCT00082511?
This trial is sponsored by Genelabs Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00082511 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
RECRUITING · Phase 3
-
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.